Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9129967 | 1.00 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL9064096 | 1.00 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL9129957 | 1.00 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL38250 | 0.98 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL38251 | 0.98 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL26696282 | 0.94 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NR1H4 | |
| SCHEMBL29263941 | 0.89 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL1718737 | 0.89 | — | — | |
| SCHEMBL1718738 | 0.89 | — | — | |
| SCHEMBL27325445 | 0.82 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2NPSR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1311012-C | Surface treatment agent of acrylonitrile-butadiene-phenylethylene shaping object | LEJIN ELECTRONIC TIANJIN ELEC (CN) | 2007-04-18 | — | — | CN | claimed |
| CN-1442442-A | Surface treatment agent of acrylonitrile-butadiene-phenylethylene shaping object | LEJIN ELECTRONIC TIANJIN ELEC (CN) | 2003-09-17 | — | — | CN | claimed |
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| CN-101193882-B | N-Formyl Hydroxylamine Compounds as PDF Inhibitors | NOVARTIS AG | 2011-09-07 | — | — | CN | disclosed |
| CN-101333297-B | Organic/inorganic hybrid material and method for forming the same | IND TECH RES INST | 2011-06-29 | — | — | CN | disclosed |
| CN-101395148-A | N-formyl hydroxylamine compounds | NOVARTIS AG (CH) | 2009-03-25 | — | — | CN | disclosed |
| CN-101333297-A | Organic/inorganic hybrid material and method for forming the same | IND TECH RES INST (CN) | 2008-12-31 | — | — | CN | disclosed |
| CN-101193882-A | N-formyl hydroxylamine compounds as PDF inhibitors | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | disclosed |
| CN-1311012-C | Surface treatment agent of acrylonitrile-butadiene-phenylethylene shaping object | LEJIN ELECTRONIC TIANJIN ELEC (CN) | 2007-04-18 | — | — | CN | disclosed |
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| CN-1442442-A | Surface treatment agent of acrylonitrile-butadiene-phenylethylene shaping object | LEJIN ELECTRONIC TIANJIN ELEC (CN) | 2003-09-17 | — | — | CN | disclosed |
| CN-1394240-A | Organic coating covered steel sheet and manufacturing method thereof | NIPPON KOKAN KK (JP) | 2003-01-29 | — | — | CN | disclosed |
| US-5545666-A | CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-13 | — | — | US | disclosed |
| EP-0666256-A1 | PROSTAGLANDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | HCAR2 4097/4885KEAP1 101/4885NFE2L2 888/4885 |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | HCAR2 3241/4885KEAP1 345/4885NFE2L2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.